31 years of historical data (1995–2025) · Healthcare · Medical - Devices
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
LivaNova PLC currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis. On a free-cash-flow basis, the stock trades at 24.9x P/FCF, 47% below the 5-year average of 46.8x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $4.3B | $3.4B | $2.5B | $2.8B | $3.0B | $4.4B | $3.2B | $3.6B | $4.4B | $3.9B | $2.2B |
| Enterprise Value | $4.1B | $3.2B | $2.8B | $3.2B | $3.3B | $4.5B | $3.7B | $4.0B | $4.6B | $3.9B | $2.3B |
| P/E Ratio → | -17.64 | — | 39.92 | 161.69 | — | — | — | — | — | — | — |
| P/S Ratio | 3.11 | 2.42 | 2.02 | 2.43 | 2.91 | 4.28 | 3.44 | 3.36 | 4.01 | 3.83 | 1.81 |
| P/B Ratio | 3.57 | 2.79 | 1.91 | 2.20 | 2.46 | 3.42 | 2.90 | 2.64 | 2.95 | 2.14 | 1.29 |
| P/FCF | 24.90 | 19.36 | 18.59 | 70.24 | 68.47 | 57.44 | — | — | 53.77 | 67.76 | 41.49 |
| P/OCF | 16.96 | 13.19 | 13.81 | 37.44 | 42.51 | 43.17 | — | — | 36.81 | 42.45 | 24.38 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
LivaNova PLC's enterprise value stands at 17.2x EBITDA, 46% below its 5-year average of 31.9x. The Healthcare sector median is 14.2x, placing the stock at a 21% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.30 | 2.21 | 2.76 | 3.27 | 4.35 | 3.93 | 3.67 | 4.12 | 3.88 | 1.88 |
| EV / EBITDA | 17.19 | 13.22 | 15.40 | — | — | 67.04 | — | — | — | 23.68 | 63.46 |
| EV / EBIT | 20.81 | — | 18.33 | — | — | — | — | 82.09 | — | 30.47 | 63.70 |
| EV / FCF | — | 18.42 | 20.42 | 79.60 | 76.90 | 58.46 | — | — | 55.24 | 68.68 | 43.06 |
Margins and return-on-capital ratios measuring operating efficiency
LivaNova PLC earns an operating margin of 14.4%. Operating margins have expanded from -5.9% to 14.4% over the past 3 years, signaling improving operational efficiency. A negative ROE of -19.2% indicates the company is currently destroying shareholder equity. ROIC of 11.5% represents solid returns on invested capital.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 67.7% | 67.7% | 69.5% | 66.9% | 69.2% | 68.2% | 63.7% | 66.8% | 66.4% | 64.4% | 58.0% |
| Operating Margin | 14.4% | 14.4% | 10.3% | -5.9% | -7.5% | -0.1% | -29.3% | -15.8% | -22.4% | 9.5% | -2.3% |
| Net Profit Margin | -17.5% | -17.5% | 5.0% | 1.5% | -8.4% | -13.1% | -37.3% | -14.5% | -17.1% | -2.5% | -5.2% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -19.2% | -19.2% | 4.9% | 1.4% | -6.9% | -11.3% | -28.0% | -10.9% | -11.4% | -1.4% | -3.6% |
| ROA | -9.5% | -9.5% | 2.6% | 0.7% | -3.8% | -5.9% | -14.5% | -6.4% | -7.5% | -1.0% | -2.6% |
| ROIC | 11.5% | 11.5% | 6.0% | -3.2% | -3.9% | -0.0% | -12.5% | -7.7% | -10.7% | 3.9% | -1.1% |
| ROCE | 10.2% | 10.2% | 6.1% | -3.3% | -4.4% | -0.0% | -13.7% | -8.7% | -12.0% | 4.6% | -1.3% |
Solvency and debt-coverage ratios — lower is generally safer
LivaNova PLC carries a Debt/EBITDA ratio of 2.0x, which is manageable (39% below the sector average of 3.2x). The company holds a net cash position — cash of $636M exceeds total debt of $473M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.39 | 0.39 | 0.51 | 0.50 | 0.48 | 0.22 | 0.64 | 0.29 | 0.11 | 0.08 | 0.07 |
| Debt / EBITDA | 1.96 | 1.96 | 3.76 | — | — | 4.27 | — | — | — | 0.88 | 3.42 |
| Net Debt / Equity | — | -0.14 | 0.19 | 0.29 | 0.30 | 0.06 | 0.41 | 0.24 | 0.08 | 0.03 | 0.05 |
| Net Debt / EBITDA | -0.67 | -0.67 | 1.38 | — | — | 1.17 | — | — | — | 0.32 | 2.31 |
| Debt / FCF | — | -0.94 | 1.82 | 9.36 | 8.44 | 1.02 | — | — | 1.47 | 0.92 | 1.57 |
| Interest Coverage | -3.48 | -3.48 | 2.40 | -0.38 | -0.56 | -1.48 | -1.49 | 3.21 | -24.19 | 16.54 | 3.37 |
Net cash position: cash ($636M) exceeds total debt ($473M)
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.36x means LivaNova PLC can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has declined from 2.95x to 1.36x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.36 | 1.36 | 2.87 | 2.95 | 2.98 | 0.97 | 2.29 | 1.07 | 1.07 | 2.14 | 1.96 |
| Quick Ratio | 1.16 | 1.16 | 2.50 | 2.51 | 2.54 | 0.82 | 1.92 | 0.75 | 0.76 | 1.79 | 1.38 |
| Cash Ratio | 0.79 | 0.79 | 1.09 | 0.80 | 0.72 | 0.30 | 0.82 | 0.12 | 0.10 | 0.23 | 0.13 |
| Asset Turnover | — | 0.53 | 0.50 | 0.47 | 0.45 | 0.47 | 0.39 | 0.45 | 0.43 | 0.40 | 0.52 |
| Inventory Turnover | 2.72 | 2.72 | 2.59 | 2.59 | 2.43 | 3.11 | 2.94 | 2.20 | 2.43 | 2.50 | 2.78 |
| Days Sales Outstanding | — | 56.80 | 65.14 | 68.05 | 76.74 | 78.61 | 72.34 | 86.98 | 84.44 | 103.20 | 64.12 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
LivaNova PLC returns 0.1% to shareholders annually primarily through share buybacks.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | 2.5% | 0.6% | — | — | — | — | — | — | — |
| FCF Yield | 4.0% | 5.2% | 5.4% | 1.4% | 1.5% | 1.7% | — | — | 1.9% | 1.5% | 2.4% |
| Buyback Yield | 0.1% | 0.1% | 0.3% | 0.3% | 0.3% | 0.0% | 0.2% | 0.2% | 1.4% | 0.1% | 2.5% |
| Total Shareholder Yield | 0.1% | 0.1% | 0.3% | 0.3% | 0.3% | 0.0% | 0.2% | 0.2% | 1.4% | 0.1% | 2.5% |
| Shares Outstanding | — | $55M | $55M | $54M | $54M | $51M | $49M | $48M | $48M | $49M | $49M |
Compare LIVN with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| $4B | -17.6 | 17.2 | 24.9 | 67.7% | 14.4% | -19.2% | 11.5% | 2.0 | |
| $2B | -11.7 | — | — | 74.5% | -23.5% | -38.9% | -16.4% | — | |
| $2B | 6.8 | 6.8 | 8.5 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 | |
| $8B | -39.8 | — | — | 77.5% | -17.1% | -26.4% | -9.2% | — | |
| $102B | 22.0 | 14.5 | 19.6 | 65.3% | 17.8% | 9.4% | 6.0% | 3.2 | |
| $154B | 11.6 | 16.1 | 24.2 | 50.8% | 16.3% | 30.9% | 9.9% | 1.5 | |
| $67B | 23.3 | 20.8 | 18.4 | 69.0% | 19.8% | 12.4% | 8.8% | 3.3 | |
| $118B | 36.6 | 21.2 | 27.5 | 64.0% | 19.5% | 15.1% | 11.4% | 2.4 | |
| $320M | 45.0 | 27.6 | 28.9 | 78.1% | 15.4% | 17.2% | 26.1% | 0.0 | |
| $17B | 30.5 | 17.4 | 18.4 | 61.0% | 17.4% | 11.1% | 9.4% | 2.6 | |
| $144B | 51.7 | 39.0 | 58.0 | 66.0% | 29.3% | 16.6% | 15.0% | 0.1 | |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Includes 30+ ratios · 30 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying LIVN stock.
LivaNova PLC's current P/E ratio is -17.6x. The historical average is 100.8x.
LivaNova PLC's current EV/EBITDA is 17.2x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 36.6x.
LivaNova PLC's return on equity (ROE) is -19.2%. The historical average is -18.7%.
Based on historical data, LivaNova PLC is trading at a P/E of -17.6x. Compare with industry peers and growth rates for a complete picture.
LivaNova PLC has 67.7% gross margin and 14.4% operating margin. Operating margin between 10-20% is typical for established companies.
LivaNova PLC's Debt/EBITDA ratio is 2.0x, indicating moderate leverage. A ratio below 2x is generally considered financially healthy.